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Abstract 
A series of 1-aryl-3,4-substituted-1H-pyrazol-5-ol derivatives was synthesized and evaluated as prostate cancer 
antigen-1 (PCA-1/ALKBH3) inhibitors to obtain a novel anti-prostate cancer drug. After modifying 
1-(1H-benzimidazol-2-yl)-3,4-dimethyl-1H-pyrazol-5-ol (1), a hit compound found during random screening using a 
recombinant PCA-1/ALKBH3, 1-(1H-5-methylbenzimidazol-2-yl)-4-benzyl-3-methyl-1H-pyrazol-5-ol (35, 
HUHS015), was obtained as a potent PCA-1/ALKBH3 inhibitor both in vitro and in vivo. The bioavailability (BA) of 
35 was 7.2% in rats after oral administration. As expected, continuously administering 35 significantly suppressed the 
growth of DU145 cells, which are human hormone-independent prostate cancer cells, in a mouse xenograft model 
without untoward effects. 
 
Prostate cancer is highly serious when malignant, and developing novel anti-prostate cancer drugs that are effective 
against both androgen-dependent and independent types is now urgently required.1 Tsujikawa et al. have reported a 
novel gene that encodes a DNA and/or RNA-alkylating damage-repair enzyme called prostate cancer antigen (PCA)-12 
or AlkB homologue 3 (ALKBH3) that is highly expressed in clinical prostate cancer cells; genetic inhibition of the 
enzymatic activity by injecting siRNA effectively inhibited the growth of androgen-independent prostate cancer cells, 
such as DU145, that express high levels of PCA-1/ALKBH3.3, 4  In addition, losing PCA-1/ALKBH3 led to 
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3-methylcytosine accumulation and reduced cell proliferation in various cell lines.5  Therefore, a small, orally 
available PCA-1/ALKBH3 inhibitor would be a novel and clinically effective anti-prostate cancer drug, even for 
hormone-independent varieties. Random screening using commercially available 17,000-compound libraries and 
recombinant PCA-1/ALKBH3 has been carried out to identify small PCA-1/ALKBH3 inhibitors; 
1-(1H-benzimidazol-2-yl)-3,4-dimethyl-1H-pyrazol-5-ol (1) is a hit compound with 61% inhibition at 10 µM, and its 
inhibitory activity was confirmed with 76% inhibition at the same concentration using re-synthesized 1 (Fig. 1).   
However, 1 demonstrated only a 0.8% inhibitory effect against the proliferation of DU145 cells at 10 µM.  
Accordingly, we focused our efforts to obtain a novel PCA-1/ALKBH3 inhibitor that is effective in cell assays and in 
vivo. 
We report the design and synthesis of novel 1-ary-3,4-substituted-1H-pyrazol-5-ol derivatives and their 
PCA-1/ALKBH3 inhibitory activities and anti-cancer effects in vivo. Among them, 
1-(5-methyl-1H-benzimidazol-2-yl)-4-benzyl-3-methyl-1H-pyrazol-5-ol (35, HUHS015) was a potent 
PCA-1/ALKBH3 inhibitor that significantly suppressed the growth of DU145 cells in vitro and in a mouse xenograft 
model. These small PCA-1/ALKBH3 inhibitors are highly important because PCA-1/ALKBH3 is associated with 
numerous cancers, such as lung5, 6 and pancreatic cancers.5, 7 
 
Figure 1 
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The substituted pyrazoles evaluated in this work were synthesized by condensing N-substituted hydrazines (3) with 
ethyl acetoacetate derivatives (4)8 (Scheme 1). The assay methods for PCA-1 inhibitory activities and biological assays 
in vitro and in vivo of these compounds were shown in Supplementary data. 
Scheme 1 
   The deletion and replacement of the aromatic rings on the benzimidazole portion of 1 generated only weak 
anti-PCA-1/ALKBH3 activities, indicating the importance of the benzimidazole (5-13, Table 1). Only compounds with 
a methyl group at the 5 position of benzimidazole (12) demonstrated slightly more potent anti-PCA-1/ALKBH3 
activity.  Structurally similar 1-aryl-3,4-substituted-pyrazol-5-ol compounds, such as the 1-(2-pyridyl)-pyrazol-5-ol 
derivative (2), were recently reported to block divalent metal transporter 1 (DMT1, Fig. 1).9 In these DMT1 blockers, 
the neighboring basic nitrogen in the aryl ring was vital for metal chelation and DMT1 inhibitory activities.   
However, a similar 2-pyridyl derivative (11) examined in this study revealed only weak PCA-1/ALKBH3 inhibition 
and attenuated inhibitory activities against DU145 cell proliferation (data not shown).  The basicity of the N atom on 
the benzimidazole studied in this work is weak, and its metal chelating ability should be poor.  Therefore, we 
proposed that metal chelation contributed little to the PCA-1/ALKBH3 inhibitory activities.  This result was favorable 
for developing a clinically useful anti-cancer drug because metal chelators often cause adverse effects or toxicity in 
vivo. 
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Table 1 and Table 2 
 
 Based on the above results, we fixed 1H-benzimidazol-2-yl at the 1 position of the pyrazole ring and evaluated 
1-(substituted-1H-benzimidazole-2-yl)-3,4-substituted-1H-pyrazol-5-ol derivatives (14-24, Table 1).  Introducing a 
phenyl (15) or naphthyl (16) group on the methyl group at the 4 position of the pyrazole generated potent 
PCA-1/ALKBH3 inhibitory effects, while the compounds without the methyl (14) group or with a carboxyl moiety (17 
and 18) demonstrated similar activities.  Derivatives with a phenyl ring at the 3 position (19-24) exhibited weaker 
activities.   Accordingly, we fixed the methyl and benzyl groups at the 3 and 4 positions, respectively, for further 
studies. 
  The substituent effects on the phenyl group in 15 were evaluated (25-34, Table 2). However, no enhancement of 
anti-PCA-1/ALKBH3 activities was observed. In particular, the derivative with an ortho-chloro substituent (25 and 28) 
greatly decreased the inhibitory activity. Therefore, a benzyl group was used at the 4 position, and the derivatives 
bearing benzimidazole ring substituents were evaluated (35-44, Table 2). Some derivatives with substitution at the 5 
position, such as 35 and 37-40, exhibited potent PCA-1/ALKBH3 inhibitory activity, while compounds with 
substituents at the 4 position, such as 43 and 44, displayed reduced activity. Of these compounds, 35 (HUHS015) was 
selected for further study because it potently inhibited PCA-1/ALKBH3 and had good physical properties.  Finally, 
the substituents on the phenyl ring of 35 were varied (45-52, Table 2). The inhibitory activities of those derivatives 
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were similar to that of 35 and therefore were not pursued.   
 Next, we selected several compounds and tested the proliferation inhibition against DU145 cells and the oral 
availability in rats (Table 3). The proliferation inhibition of DU145 was examined in both an ordinary 
anchorage-dependent assay on dishes and an anchorage-independent assay using soft-agar because the inhibitory 
activity against the latter cells might be crucial to clinical efficacy.10 Compounds with weak PCA-1/ALKBH3 
inhibitory activity, such as 12, demonstrated weak proliferation inhibition against DU145, while those with 
sub-micromolar IC50 values, such as 15, 35, 38, and 49, exhibited more potent effects. We are uncertain about the 
potency of 36 in the DU145 assays because its IC50 value during the PCA-1/ALKBH3 enzyme assay was 4.5 µM or 
weaker. Consequently, 36 was eliminated from further studies because these inconsistent effects might cause 
unexpected side effects in future studies. To select a compound for additional in vivo studies, we also measured the 
blood concentration 1 h after each compound was orally administered (32 mg/kg). Compound 12 exhibited high serum 
concentrations relative to the other derivatives. However, compounds with relatively high molecular weights, such as 
41, exhibited poor oral absorbability. Therefore, smaller compounds were more bioavailable. Consequently, we 
selected 35 (HUHS015) for further studies because it exhibited an adequate level of serum concentration after oral 
administration and potent inhibition during both the enzymatic and cell assays. We measured the preliminary 
bioavailability (BA) value for 35 after oral administration to rats, revealing a 7.2% BA value (Figs. S1 and S2). This 
BA value was sufficient for continuing the in vivo studies.   
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Table 3 and Figure 2 
 
 The growth inhibition demonstrated by 35 (32 mg/kg) was examined in a mouse xenograft model bearing DU145 
after subcutaneous injection (Fig. 2); potent growth inhibition was observed without limiting weight gains, even after a 
6-day continuous administration.11 Therefore, the synthesizing small molecule inhibitor of PCA-1/ALKBH3, a 
clinically identified novel target, demonstrated promising results for developing an anti-prostate cancer drug without 
mechanism-oriented side effects. Now further modifications of 35 to obtain more potent inhibitors and combination 
studies with 35 and clinically used drug such as docetaxel are in progress, and will be reported in the near future. 
In conclusion, we synthesized 1,3,4-substituted-1H-pyrazol-5-ol derivatives to identify orally active 
PCA-1/ALKBH3 inhibitors and selected 1-(5-methyl-1H-benzimidazol-2-yl)-4-benzyl-3-methylpyrazol-5-ol (35, 
HUHS015) for further analysis. Compound 35 exhibited potent inhibition against DU145 proliferation without 
observable side effects after subcutaneous administration in a xenografted mouse model. The results for 35 
(HUHS015) in the xenograft mouse model, when combined with previously reported PCA-1/ALKBH3 knock-out mice 
study,12 in which mice lacking function of ALKBH3 gene are viable without overt phenotypes and histological changes, 
demonstrated that small PCA-1/ALKBH3 inhibitors would be effective drugs against prostate cancer without 
mechanism-based side effects or toxicity.   
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Figure 1.  Structure of PCA-1/ALKBH3 inhibitor obtained in 
our random screening and previously known DMT1 blocker. 
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Figure 2.   (a) Inhibitory effect of HUHS015 (35, 32 mg/kg/day, open circle) on 
the growth of subcutaneously implanted DU145 (nude mice) was examined (n = 
6).  Compound 35 or saline was administered for 6 days (arrows), and the tumor 
volume was measured for 10 days. Black circles demarcate the control data 
(0.5% methylcellulose).    (b) The mice administered with 35 (white circle) 
gained more body weight than the control mice (black circle).   No apparent 
toxicity or side effects were found in the mice during the experiment.   The 
values represent means ± SE (n = 6). 
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Scheme 1. 
Bezimidazol-2-yl     Me      Me                 4.0  
Phenyl                          Me      Me             >10 (20%) 
Benzthiazol-2-yl     Me      Me             >10 (-3%) 
Benzoxazol-2-yl     Me      Me             >10 (0%) 
1-Me-benzimidazol-2-yl     Me      Me             >10 (21%) 
    2-Pyrimidyl     Me      Me             >10 (-4%) 
      2-Pyridyl                           Me      Me             >10 (-4%)   
5-Me-benzimidazol-2-yl      Me      Me                  2.6  
4-Me-benzimidazol-2-yl      Me      Me             >10 (-28%) 
Benzimidazol-2-yl       H      Me                  3.6  
Benzimidazol-2-yl   Benzyl      Me                  0.48  
Benzimidazol-2-yl           2-Naphtylmethyl    Me                  0.75  
Benzimidazol-2-yl CH2COOMe      Me                  4.3  
Benzimidazol-2-yl CH2COOH      Me                15.0  
Benzimidazol-2-yl       H   Phenyl               7.2  
Benzimidazol-2-yl      Me   Phenyl           >10 (-11%) 
Benzimidazol-2-yl    Benzyl   Phenyl           >10 (2%) 
5-Me-benzimidazol-2-yl      Me   Phenyl               3.3  
5-Cl-benzimidazol-2-yl    Phenyl   Phenyl               2.0  
5-Me-benzimidazol-2-yl    Phenyl   Phenyl               5.8  
R1                                                R2                          R3 
PCA-1 
inhibition 
IC50 (µM) 
Table 1. PCA-1 inhibitory activities of 1,3,4-substituted-5-hydroxy-pyrazoles 
R1 N
N
HO
R3
R2
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
R1                         R2      
PCA-1 
inhibition 
IC50 (µM) 
Table 2.  PCA-1 inhibitory activities of 1-(substituted benzimidazol-2-
yl)-5-hydroxy-3-methyl-4-(subsituted benzyl) pyrazoles 
N
N
HO
MeN
N
H
R1
R2
        H                  2-Cl                           >10 (-13%) 
        H                  3-Cl                        0.54 
        H                  4-Cl                           >10 (46%) 
        H                2,4-Cl2                         >10 (11%) 
        H                3,4-Cl2                         3.1 
        H                  4-CF3                        0.55 
        H                   4-F                              0.60 
        H                 4-MeO                          0.63 
        H               4-Phenyl                         0.72 
        H                  4-tBu                        4.1 
      5-Me                 H                               0.67 
      5-Cl                   H                             4.5 
      5-Br                   H                             0.49 
     5-CF3                 H                               0.61 
     5-tBu                  H                             0.64 
   5-Phenyl               H                             0.81 
5-(4-Cl-phenyl)        H                             1.5 
5-(4-Me-phenyl)       H                             2.1 
       4-Me                 H                             5.9 
     4,5-Me2               H                           >10 (-47%) 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
R1                               R2      
PCA-1 
inhibition 
IC50 (µM) 
Table 2.  (continued) 
    5-Me            4-CF3                      0.57 
    5-Me            4-MeO                    0.68 
    5-Me            3,4-Cl2                    0.72 
    5-Me              2-Cl                       0.91 
    5-Me                      4-Cl                       0.75 
    5-Me              4-F                        0.78 
    5-Me             4-tBu                     3.7 
    5-Me           4-Phenyl                  5.3 
45 
46 
47 
48 
49 
50 
51 
52 
10 µM(%) 1 µM(%) 10 µM(%) 1 µM(%)   
  47            42             90            42                            NTa 
  19           -11    69    3.8                  1080 
  54   35    81    34                    81 
  NT   86    87    84                   154 
  84   78    92    90                    20 
  63   70   100    91                             7 
  46   -1    90    2.8                           72 
  
Inhibition (%) on DU145 proliferation 
2D assay 3D assay 
Serum concentration 
at 1 h 
(µg/mL) 
Table 3.  Inhibitory activities of DU145 cells proliferation on dish (2-D assay) and 
in agar (3-D assay), and serum concentration at 1 h after oral administration (32 
mg/kg). 
15 
12 
35 
36 
38 
41 
49 
a NT: not tested. 
Supplemental experiment data 
Thin-layer chromatography (TLC) was performed on Merck silica gel 60 F254 plate.  
For normal chromatography, Merck silica gel type 60 (size 5-40 µm) was used.  All 
evaporation was performed with a rotary evaporator under reduced atmosphere. The 
structures of all compounds were confirmed by a LC-MS (Brucker, micrOTOF-Q), a 
FT-IR(JEOL, FT/IR-4100), and 400MHz proton nuclear magnetic resonance spectrum 
(JEOL, ECX-400PKS).  The chemical shift values are reported in parts per million on 
the δ scale from internal standard tetramethylsilane.  No attempt was made to 
maximize the yields.  Purity of the synthesized compounds was determined using the 
HPLC method with UV detector at the absorption wavelength of 254 nm.  Purity of all 
biologically estimated compounds was ≥95%. 
Typical experimental procedure for substituted 1,3-dihydrobenzimidazol-2-one  
  To a solution of 4-methyl-1,2-phenylenediamine (25 g, 0.205 mol) in 
tetrahydrofuran (375 mL) was added dropwise a solution of 1,1'-carbonyldiimidazole 
(36.5 g, 0.225 mol) in dichloromethane (375 mL).  After stirring for 6.5 h at ambient 
NH2
NH2
Me Me
N
H
H
N
O
temperature, to the reaction mixture was added diisopropyl ether (375 mL). After 
stirring at ambient temperature, the resulting precipitates were collected by filtration. 
The precipitates were washed with diisopropyl ether and dried in vacuo to give 
5-methyl-1,3-dihydrobenzimidazol-2-one (24.6 g, 70.1%).  ESI-HRMS calcd. for 
C8H8N2ONa([M+Na]
+) 171.0529; found m/z 171.0529.  NMR (DMSO-d6, δ): 2.27(3 
H, s), 6.70-6.81(3 H, m), 10.46(2 H, br. s).    
Typical experimental procedure for substituted 2-chloro-benzimidazol    
 A mixture of 5-methyl-1,3-dihydrobenzimidazol-2-one (1.00 g, 6.84 mmol) and 
phosphorous oxychloride (9.54 mL, 103 mmol) was stirred for 1.5 h at 95 oC.   After 
being cooled to ambient temperature, the reaction mixture was carefully added to a 
mixture of saturated NaHCO3 aq. (60 mL) and ethyl acetate (60 mL).  The separated 
organic layer was washed with water, brine, and dried over MgSO4.  After filtration, 
the filtrate was evaporated in vacuo,  The resulting precipitates were collected by 
filtration, and successfully washed with isopropyl ether to give 
2-chloro-5-methyl-benzimidazole (1.74 g, 58.9 %).  ESI-HRMS calcd. for C8H8ClN2 
([M+H]+) 167.0371; found m/z 167.039.   NMR (DMSO-d6, δ): 2.40 (3 H, s), 
Me
N
H
H
N
O
Me
N
H
N
Cl
7.00-7.06 (1H,m), 7.29 (1 H, s), 7.39 (1 H, d, J=8.2 Hz).  Other substituted 
2-chloro-benzimidazols were prepared in a manner similar. 
Typical experimental procedure for substituted 2-hydrazino-benzimidazol (3) 
  A mixture of 2-chloro-5-methyl-benzimidazole (10.2 g, 61.2 mmol) and hydrazine 
monohydrate (59 mL, 1.22 mol) was stirred at 100 oC  overnight. After being cooled to 
ambient temperature, to the reaction mixture was added to water (60 mL). After stirring 
under ice cooling, the resulting precipitates were collected by filtration. The precipitates 
were washed with water 3 times, and then dried in vacuo to give 
2-hydrazino-5-methyl-benzimidazole (8.4 g, 84.6%).  ESI-HRMS calcd. for 
C8H11N4([M+H]
+) 163.0978; found  m/z 163.0985.   NMR (DMSO-d6, δ): 2.30 (3 H, 
s), 4.39 (2 H, br. s), 6.63-6.70 (1 H, m), 6.91-6.94 (1 H, m), 6.97-7.01 (1 H, m), 7.69 (1 
H, br. s), 10.87 (1 H, br. s).  Other substituted hydrazine derivatives (3) were prepared 
in a similar manner. 
Me
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Cell culture.  The human prostate cancer cell line DU145 was supplied from the Cell 
Resource Center for Biomedical Research Institute of Development, Aging, and Cancer, 
Tohoku University, Japan..  The cell line was maintained in Dulbecco's modified Eagle 
medium (DMEM) supplemented with 10% fetal calf serum (FCS) and 100 μg/mL 
kanamycin at 37°C under a humidified atmosphere containing 5% CO2.  
Animal care.   Male nude mice of BALB/c background were purchased from Charles 
River Japan Inc., Tokyo.  Male Sprague-Dawley (SD) rats were purchased from Japan 
SLC Inc. (Shizuoka, Japan).  Animals were kept under conditions of constant 
temperature and humidity, and fed a standard diet and water ad libitum. All animal 
experiments in this study were approved by our institutional animal care committee. 
PCA-1 inhibitory activity.    An assay system of PCA-1 demethylase inhibitors was 
described elsewhere. Briefly, 4 ng of PCA-1 with or without compounds was incubated 
with 80 fmol 3-methyl cytosine oligo DNA (100 bp) as a substrate to be demethylated 
in buffer (50 mM Tris-HCl (pH8.0), 2 mM ascorbic acid, 100 μM oxoglutarate, and 40 
μM ferrous sulfate) and incubated at 37°C for 1 hour. Then, the reaction was stopped by 
dilution to 20 times volume by water.   Two μL of the above samples was used as 
templates of real-time PCR using Bio-Rad iQ SYBR Green Supermix to 20 μL. 
Standard curve was given using oligo DNA without methylation as templates. The 
cycling conditions consisted of an initial, single cycle at 95°C for 10 sec followed by 40 
cycles of at 95°C for 5 sec, at 61°C for 30 sec, and at 72°C for 15 sec. The PCA-1 
inhibition effects of compounds were determined by quantitative analysis with real-time 
PCR.  
Inhibitory effect of compounds on proliferation of DU145 by anchorage-dependent 
(on dish) cell culture.    The experiments to examine the inhibitory effects of 
compounds with DU145 cells proliferation were carried out in a 96-well plate and the 
number of viable cells at the end of incubation was determined by WST 
((2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, 
monosodium salt)) assay, which is determined by measuring the capacity of the cells to 
reduce WST to formazan. Briefly, 5 x 103 cells / well in 90 μL cultured medium were 
incubated in the presence or absence of compounds for 48 hours. After addition of 10 
μL of WST-1/1-methoxy-5-methylphenazinium methylsulfate solution, the plates were 
incubated at 37°C in a humidified atmosphere containing 5% CO2 for 2 hours. 
Absorbance was measured using a microplate reader with a test wavelength of 450 nm 
and a reference wavelength of 630 nm. Then, the percent of inhibition of each 
compound was calculated. 
Inhibitory effect of compounds on proliferation of DU145 by 
anchorage-independent (in agar, 3D assay) cell culture.  Inhibitory effects of the 
compounds on proliferation of DU145 cells in 3D cell culture were examined by 
assaying colony formation in soft agar. Briefly, DU145 cells were suspended to 1.3 x 
105 cells /mL in DMEM with 0.4% Agarose, 10 % FCS and antibiotics, then, 75 μL of 
that containing 1 × 104 cells were plated on the bottom layer that consisted with 0.6% 
agarose containing DMEM 10 % FCS in 96 well plates. The plates were placed at 4°C 
for 5 min to harden and warmed at 37°C in a humidified atmosphere containing 5% CO2. 
Hundred μL of the compound solutions were added on the each well.  The cell 
numbers after 7 days were determined with the capacity of the cells to reduce 12 μL of 
5 mM WST to formazan at 37 °C for 2 hours by measurement of absorbance at 450 nm. 
Percentages of inhibition of each compound were calculated. 
Measurement of serum concentration of compounds in rats   Male 
Sprague-Dawley (SD) rats were fasted for 18 hours, and 32 mg/kg of each compound 
suspended in 0.5 % methylcellurose (MC) was orally administrated. After 1 hour of 
administration, bloods were obtained with heparin as anticoagulant from abdominal 
vein or subclavian vein under anesthesia. The serum was then separated by 
centrifugation and all samples were stored at -30°C until analyzed.  The concentration 
of each compound was determined using HPLC. 
Measurement of bioavailability of compounds in rats   Male Sprague-Dawley (SD) 
rats were fasted for 18 hours, and 32 mg/kg of HUHS15 suspended in 0.5 % 
methylcellurose (MC) was orally or 0.5 mg/kg of HUHS15 dissolved in Sesame oil was 
intravenously administrated. After 0.25, 0.5, 1, 2, 6, 24 hours of administration, bloods 
were obtained from abdominal vein or subclavian vein under anesthesia. The 
concentration of each compound in the serum was measured using HPLC (Figure S1). 
Growth inhibitory effect of 35(HUHS15) on DU145 xenograft in mice.   Male 
nude mice of BALB/c background were implanted subcutaneously with approximately 
10 mm3 of in vivo passage tumors of DU145 cells into the right flank of the mice. When 
estimated tumor volume in the mice had reached 100 to 300 mm3, animals were divided 
into 2 experimental groups of 6 mice and treated subcutaneously with 32 mg/kg of 
HUHS15 suspended in 0.5 % MC for 6 days everyday. The tumor volume was 
calculated on day 0, 1, 3, 6, and 10 from the following formula: tumor volume (mm3) = 
LxW2/2, where L and W represent the length and the width of the tumor mass, 
respectively. The changes of tumor volume before administration were calculated. 
Results are shown as means ± SE of 6 mice and analyzed statistical significance by 
t-test.  
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N M R ( D M S O- d 6 , δ): 1. 7 7 ( 3 H, s), 2. 1 7 ( 3 H, s), 7. 1 2- 7. 1 8 ( 2 H, m), 7. 5 0- 7. 5 5 ( 2 H, m) I R ( K Br): 3 2 9 6, 3 0 4 9, 2 9 2 1, 2 8 6 2,
1 6 2 6, 1 5 4 7 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 2 H 1 3 N 4 O ([ M + H] + ) 2 2 9. 1 0 8 4 ;
f ou n d 2 2 9. 1 0 9 1
8. 5 9 8. 3
6
N M R ( D M S O- d 6 , δ): 1. 7 6 ( 3 H, s), 2. 0 9 ( 3 H, s), 7. 1 4- 7. 2 0 ( 1 H, m), 7. 3 8- 7. 4 4 ( 2 H, m),
7 . 7 1 ( 2 H, d, J = 7. 8 H z)
I R ( K Br): 3 4 3 1, 3 0 4 6, 2 8 5 9, 2 7 9 6,
1 5 9 1 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 1 H 1 3 N 2 O ([ M + H] + ) 1 8 9. 1 0 2 2 ;
f ou n d 1 8 9. 1 0 3 5
8. 6 9 6. 7
7
N M R ( D M S O- d 6 , δ): 1. 7 6 ( 3 H, s), 2. 2 0 ( 3 H, s), 7. 3 3- 7. 3 8 ( 1 H, m), 7. 4 6- 7. 5 1 ( 1 H, m),
7 . 8 0- 7. 8 4 ( 1 H, m), 8. 0 3- 8. 0 7 ( 1 H, m)
I R ( K Br): 3 0 6 7, 2 9 2 4, 1 6 4 4, 1 5 9 6,
1 5 2 8 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 2 H 1 2 N 3 O S ([ M + H] + ) 2 4 6. 0 6 9 6 ;
f ou n d 2 4 6. 0 7 1 0
1 1. 3 9 8. 3
8
N M R ( D M S O- d 6 , δ): 1. 7 7 ( 3 H, s), 2. 1 5 ( 3 H, s), 7. 3 2- 7. 4 1 ( 2 H, m), 7. 6 5- 7. 7 5 ( 2 H, m) I R ( K Br): 3 0 8 2, 2 9 1 9, 1 6 3 3, 1 6 0 9,
1 5 6 1 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 2 H 1 2 N 3 O 2  ([ M + H]+ ) 2 3 0. 0 9 2 4 ;
f ou n d 2 3 0. 0 9 3 0
9. 9 9 8. 8
9
N M R ( C D Cl 3 , δ): 1. 9 3 ( 3 H, s), 2. 2 2 ( 3 H, s), 4. 2 4 ( 3 H, s), 7. 2 6- 7. 3 6 ( 3 H, m), 7. 5 6- 7. 6 1
( 1H, m)
I R ( K Br): 3 4 3 1, 3 0 5 8, 2 9 2 2, 2 8 6 1,
1 6 6 5, 1 5 6 1, 1 5 1 1 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 3 H 1 5 N 4 O ([ M + H] + ) 2 4 3. 1 2 4 0 ;
f ou n d 2 4 3. 1 2 4 8
8. 7 9 8. 6
1 0
N M R ( D M S O- d 6 , δ): 1. 7 3 ( 3 H, s), 2. 1 1 ( 3 H, s), 7. 3 1 ( 1 H, t, J  = 4. 8 H z), 8. 7 7 ( 2 H, d, J =
4. 8 H z)
I R ( K Br): 3 4 7 6, 3 0 5 6, 2 9 2 7, 1 6 3 9,
1 5 6 8 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C9 H 1 1 N 4 O ([ M + H] + ) 1 9 1. 0 9 2 7 ;
f ou n d 1 9 1. 0 9 3 4
7. 3 9 9. 0
1 1
N M R ( D M S O- d 6 , δ): 1. 7 2 ( 3 H, s), 2. 1 2 ( 3 H, s), 7. 1 7- 7. 2 2 ( 1 H, m), 7. 8 6- 7. 9 2 ( 1 H, m),
8 . 2 8 ( 1 H, br s), 8. 3 7- 8. 4 0 ( 1 H, m)
I R ( K Br): 3 4 1 9, 3 0 6 2, 2 9 1 9, 1 6 3 3,
1 5 9 4 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 0 H 1 2 N 3 O ([ M + H] + ) 1 9 0. 0 9 7 5 ;
f ou n d 1 9 0. 0 9 7 9
9. 1 9 8. 8
1 2
N M R ( D M S O- d 6 , δ): 1. 7 7 ( 3 H, s), 2. 1 6 ( 3 H, s), 2. 3 9 ( 3 H, s), 6. 9 8 ( 1 H, d d, J  = 0. 9 a n d
8. 2 H z), 7. 3 2 ( 1 H, br s), 7. 4 0 ( 1 H, d, J = 8. 2 H z)
I R ( K Br): 3 3 0 8, 3 0 1 8, 2 9 2 0, 2 8 6 1,
1 6 3 5, 1 5 7 3  c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 3 H 1 5 N 4 O ([ M + H] + ) 2 4 3. 1 2 4 0 ;
f ou n d 2 4 3. 1 2 5 9
9. 0 9 8. 9
1 3
N M R ( D M S O- d 6 , δ): 1. 7 8 ( 3 H, s), 2. 1 8 ( 3 H, s), 2. 5 2 ( 3 H, s), 6. 9 4- 6. 9 8 ( 1 H, m), 7. 0 5
( 1H, t, J  = 7. 8 H z), 7. 3 5 ( 1 H, d, J  = 7. 8 H z)
I R ( K Br): 3 2 4 3, 2 9 1 2, 1 6 7 2, 1 6 0 6,
1 4 9 7 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 3 H 1 4 N 4 O N a ([ M + N a] + ) 2 6 5. 1 0 6 0;
f ou n d 2 6 5. 1 0 6 2
9. 2 9 8. 3
1 4
N M R ( D M S O- d 6 , δ): 2. 2 0 ( 3 H, s), 5. 2 4 ( 1 H, s), 7. 1 4- 7. 2 0 ( 2 H , m), 7. 4 9- 7. 5 5 ( 2 H, m) I R ( K Br): 3 3 1 0, 3 0 4 3, 2 9 0 5, 1 6 2 6,
1 5 5 9 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 1 H 1 1 N 4 O ([ M + H] + ) 2 1 5. 0 9 2 7 ;
f ou n d 2 1 5. 0 9 3 3
7. 3 9 8. 6
1 5
N M R ( D M S O- d 6 , δ): 2. 1 7 ( 3 H, s), 3. 6 0 ( 2 H, s), 7. 1 3- 7. 1 9 ( 3 H, m), 7. 2 4- 7. 3 0 ( 4 H, m),
7 . 4 9- 7. 5 5 ( 2 H, m)
I R ( K Br): 3 2 6 9, 3 0 2 6, 1 6 2 7, 1 5 4 2
c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 8 H 1 7 N 4 O ([ M + H] + ) 3 0 5. 1 3 9 7 ;
f ou n d 3 0 5. 1 3 9 6
1 1. 0 9 9. 0
1 6
N M R ( D M S O- d 6 , δ): 2. 1 9 ( 3 H, s), 3. 7 7 ( 2 H, s), 7. 1 3- 7. 1 8 ( 2 H, m), 7. 4 0- 7. 5 5 ( 5 H, m),
7 . 7 3 ( 1 H, br s), 7. 8 0- 7. 8 6 ( 3 H, m)
I R ( K Br): 3 0 6 8, 2 9 2 3, 1 6 4 3, 1 5 9 6,
1 5 2 8 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C2 2 H 1 9 N 4 O ([ M + H] + ) 3 5 5. 1 5 5 3 ;
f ou n d 3 5 5. 1 5 7 7
1 2. 1 9 9. 1
1 7
N M R ( M e O H- d 4 , δ): 2. 2 3 ( 3 H, s), 3. 3 9 ( 2 H, s), 3. 7 0 ( 3 H, s), 7. 2 3- 7. 2 9 ( 2 H, m), 7. 5 1-
7 . 5 8 ( 2 H, m)
I R ( K Br): 2 9 9 7, 2 9 5 0, 1 7 3 4, 1 6 9 0,
1 6 0 6, 1 5 0 0 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 4 H 1 5 N 4 O 3  ([ M + H]+ ) 2 8 7. 1 1 3 9 ;
f ou n d 2 8 7. 1 1 4 5
8. 7 9 7. 5
1 8
N M R ( D M S O- d 6 , δ): 2. 1 5 ( 3 H, s), 3. 2 2 ( 2 H, m), 7. 1 3- 7. 1 8 ( 2 H, m), 7. 4 9- 7. 5 5 ( 2 H, m) I R ( K Br): 3 4 3 3, 2 9 9 3, 1 6 9 0, 1 6 0 9,
1 5 2 5 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 3 H 1 3 N 4 O 3  ([ M + H]+ ) 2 7 3. 0 9 8 2 ;
f ou n d 2 7 3. 0 9 6 7
7. 9 9 7. 0
1 H- N M R IR E SI- H R M S
H P L C *)
1 9
N M R ( D M S O- d 6 , δ): 5. 9 4 ( 1 H, s), 7. 2 2- 7. 2 8 ( 2 H, m), 7. 3 9- 7. 5 1 ( 3 H, m), 7. 5 5- 7. 6 1 ( 2 H,
m ), 7. 8 8- 7. 9 2 ( 2 H, m)
I R ( K Br): 3 3 3 4, 3 0 6 8, 1 6 7 8, 1 6 3 1,
1 6 0 0, 1 5 5 5 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 6 H 1 3 N 4 O ([ M + H] + ) 2 7 7. 1 0 8 4 ;
f ou n d 2 7 7. 1 0 9 3
1 0. 0 9 8. 7
2 0
N M R ( D M S O- d 6 , δ): 2. 0 6 ( 3 H, s), 7. 1 8- 7. 2 4 ( 2 H, m), 7. 4 6- 7. 6 0 ( 5 H, m), 7. 7 3- 7. 7 8 ( 2 H,
m )
I R ( K Br): 3 1 7 3, 1 6 6 5, 1 6 4 0, 1 5 6 2
c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 7 H 1 5 N 4 O ([ M + H] + ) 2 9 1. 1 2 4 0 ;
f ou n d 2 9 1. 1 2 3 6
1 1. 1 9 8. 1
2 1
N M R ( D M S O- d 6 , δ): 3. 8 4 ( 2 H, s), 7. 1 3- 7. 2 9 ( 7 H, m), 7. 4 1- 7. 4 9 ( 3 H, m), 7. 5 5- 7. 6 6 ( 4 H,
m )
I R ( K Br): 3 1 8 6, 3 0 6 1, 1 6 6 5, 1 6 3 3,
1 5 9 1, 1 5 5 9 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C2 3 H 1 9 N 4 O ([ M + H] + ) 3 6 7. 1 5 5 3 ;
f ou n d 3 6 7. 1 5 6 7
1 3. 2 9 7. 8
2 2
N M R ( C D Cl 3 , δ): 2. 0 0 ( 3 H, s), 2. 4 4 ( 3 H, br s), 7. 0 6 ( 1 H, br s), 7. 1 5- 7. 5 0 ( 7 H, m), 8. 4 3
( 2H, br s)
I R ( K Br): 3 1 7 3, 3 0 2 6, 2 9 2 3, 1 6 6 2,
1 6 5 2, 1 6 3 4, 1 6 1 7, 1 5 5 8, 1 5 0 8,
1 4 7 3 c m - 1
E SI- H R M S ( n e g ati v e i o n, s o di u m f or m at e)
c a l c d f or C1 8 H 1 5 N 4 O ([ M- H] -) 3 0 3. 1 2 4 6 ;
f ou n d 3 0 3. 1 2 6 9
1 0. 7 9 7. 1
2 3
N M R ( D M S O- d 6 , δ): 7. 1 4 ( 1 H, t, J  = 7. 3 H z), 7. 2 0- 7. 3 0 ( 3 H, m), 7. 3 3 ( 2 H, d, J  = 7. 3
H z), 7. 3 7- 7. 4 5 ( 3 H, m), 7. 4 5- 7. 5 5 ( 2 H, m), 7. 5 8 ( 1 H, d, J  = 8. 7 H z), 7. 6 2 ( 1 H, br s)
I R ( K Br): 3 1 0 1, 3 0 7 3, 3 0 5 9, 1 6 5 1,
1 5 9 6, 1 5 7 2, 1 5 5 5, 1 5 1 0, 1 4 6 6 c m -
1
E SI- H R M S ( n e g ati v e i o n, s o di u m f or m at e)
c a l c d f or C2 2 H 1 4 Cl N 4 O ([ M- H] -) 3 8 5. 0 8 5 6 ;
f ou n d 3 8 5. 0 8 7 0
1 5. 0 9 9. 6
2 4
N M R ( C D Cl 3 , δ): 2. 3 9 ( 3 H, s), 7. 0 4 ( 2 H, d, J  = 7. 8 H z), 7. 0 5- 7. 5 0 ( 1 2 H, m) I R ( K Br): 3 4 1 9, 3 0 5 9, 2 9 7 4, 1 6 4 1,
1 6 1 5, 1 6 0 0, 1 5 6 5, 1 5 1 3, 1 4 6 9 c m -
1
E SI- H R M S ( n e g ati v e i o n, s o di u m f or m at e)
c a l c d f or C2 3 H 1 7 N 4 O ([ M- H] -) 3 6 5. 1 4 0 2 ;
f ou n d 3 6 5. 1 4 1 6
1 2. 9 9 7. 5
2 5
N M R ( D M S O- d 6 , δ): 2. 1 6 ( 3 H, s), 3. 6 9 ( 2 H, s), 7. 1 3- 7. 1 9 ( 2 H, m), 7. 2 0- 7. 2 9 ( 2 H, m),
7 . 3 2- 7. 3 6 ( 1 H, m), 7. 4 1- 7. 4 4 ( 1 H, m), 7. 5 0- 7. 5 5 ( 2 H, m)
I R ( K Br): 3 2 8 0, 2 9 0 0, 1 6 6 6, 1 6 1 9,
1 5 7 3  c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 8 H 1 6 Cl N 4 O ([ M + H] + ) 3 3 9. 1 0 0 7 ;
f ou n d 3 3 9. 1 0 2 2
1 1. 8 9 8. 5
2 6
N M R ( D M S O- d 6 , δ): 2. 1 9 ( 3 H, s), 3. 6 1 ( 2 H, s), 7. 1 3- 7. 1 9 ( 2 H, m), 7. 2 1- 7. 3 7 ( 4 H, m),
7 . 5 0- 7. 5 5 ( 2 H, m)
I R ( K Br): 3 3 5 0, 3 0 6 8, 2 9 1 9, 1 6 2 9,
1 5 5 3 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 8 H 1 6 Cl N 4 O ([ M + H] + ) 3 3 9. 1 0 0 7 ;
f ou n d 3 3 9. 1 0 0 6
1 1. 8 9 7. 9
2 7
N M R ( D M S O- d 6 , δ): 2. 1 7 ( 3 H, s), 3. 5 9 ( 2 H, s), 7. 1 3- 7. 1 9 ( 2 H, m), 7. 2 8- 7. 3 5 ( 4 H, m),
7 . 4 9- 7. 5 5 ( 2 H, m)
I R ( K Br): 3 2 5 9, 3 0 2 7, 2 9 3 5, 2 9 0 9,
1 5 5 6 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 8 H 1 6 Cl N 4 O ([ M + H] + ) 3 3 9. 1 0 0 7 ;
f ou n d 3 3 9. 1 0 1 0
1 1. 9 9 8. 4
2 8
N M R ( D M S O- d 6 , δ): 2. 1 6 ( 3 H, s), 3. 6 6 ( 2 H, s), 7. 1 4- 7. 1 9 ( 2 H, m), 7. 3 4- 7. 3 7 ( 2 H, m),
7 . 5 0- 7. 5 5 ( 2 H, m), 7. 5 7- 7. 5 9 ( 1 H, m)
I R ( K Br): 3 2 0 8, 3 0 6 7, 2 9 1 6, 2 8 9 7,
1 6 2 8,  1 5 5 2 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 8 H 1 5 Cl 2 N 4 O ([ M + H] + ) 3 7 3. 0 6 1 7 ;
f ou n d 3 7 3. 0 6 3 0
1 2. 9 9 8. 1
2 9
N M R ( D M S O- d 6 , δ): 2. 1 9 ( 3 H, s), 3. 6 1 ( 2 H, s), 7. 1 4- 7. 1 9 ( 2 H, m), 7. 2 8 ( 1 H, d d, J  = 1. 8
a n d 8. 2 H z), 7. 5 0- 7. 5 7 ( 4 H, m)
I R ( K Br): 3 1 8 3, 2 8 9 0, 1 6 2 6, 1 6 0 6
c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 8 H 1 5 Cl 2 N 4 O ([ M + H] + ) 3 7 3. 0 6 1 7 ;
f ou n d 3 7 3. 0 6 2 1
1 2. 6 9 9. 1
3 0
N M R ( D M S O- d 6 , δ): 2. 1 8 ( 3 H, s), 3. 6 9 ( 2 H, s), 7. 1 2- 7. 1 8 ( 2 H, m), 7. 4 7- 7. 5 4 ( 4 H, m),
7 . 6 3 ( 2 H, d, J = 8. 2 H z)
I R ( K Br): 3 2 6 3, 2 9 1 7, 1 6 6 7, 1 6 2 0,
1 5 4 8 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 9 H 1 6 F 3 N 4 O ([ M + H] + ) 3 7 3. 1 2 7 0 ;
f ou n d 3 7 3. 1 2 8 7
1 2. 2 9 8. 9
3 1
N M R ( D M S O- d 6 , δ): 2. 1 7 ( 3 H, s), 3. 5 9 ( 2 H, s), 7. 0 6- 7. 1 1 ( 2 H, m), 7. 1 4- 7. 1 8 ( 2 H, m),
7 . 2 9- 7. 3 3 ( 2 H, m), 7. 5 1- 7. 5 4 ( 2 H, m)
I R ( K Br): 3 2 4 6, 3 0 6 9, 2 9 1 0, 1 6 5 7,
1 6 0 5, 1 5 0 7 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 8 H 1 5 F N 4 O N a ([ M + N a] + ) 3 4 5. 1 1 2 2 ;
f ou n d 3 4 5. 1 1 1 4
1 1. 2 9 7. 5
3 2
N M R ( D M S O- d 6 , δ): 2. 1 5 ( 3 H, s), 3. 5 3 ( 2 H, s), 3. 7 0 ( 3 H, s), 6. 8 0- 6. 8 6 ( 2 H, m),
7 . 1 3- 7. 2 1 ( 4 H, m), 7. 5 0- 7. 5 5 ( 2 H, m)
I R ( K Br): 3 2 5 9, 3 0 4 0, 2 9 0 3, 2 8 3 4,
1 6 2 7, 1 5 4 7 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 9 H 1 9 N 4 O 2  ([ M + H]+ ) 3 3 5. 1 5 0 3 ;
f ou n d 3 3 5. 1 4 9 3
1 0. 8 9 8. 2
3 3
N M R ( D M S O- d 6 , δ): 2. 2 0 ( 3 H, s), 3. 6 4 ( 2 H, s), 7. 1 2- 7. 1 9 ( 2 H, m), 7. 3 0- 7. 4 0 ( 3 H, m),
7 . 4 1- 7. 4 7 ( 2 H, m), 7. 5 0- 7. 6 4 ( 6 H, m)
I R ( K Br): 3 2 6 7, 3 0 2 8, 1 6 5 7, 1 5 5 5
c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C2 4 H 2 1 N 4 O ([ M + H] + ) 3 8 1. 1 7 1 0 ;
f ou n d 3 8 1. 1 7 1 2
1 2. 6 9 8. 5
3 5
N M R ( D M S O- d 6 , δ): 2. 1 5 ( 3 H, s), 2. 3 9 ( 3 H, s), 3. 5 9 ( 2 H, s), 6. 9 6- 7. 0 0 ( 1 H, m), 7. 1 3-
7 . 2 0 ( 1 H, m), 7. 2 3- 7. 2 9 ( 4 H, m), 7. 3 1 ( 1 H, br s), 7. 3 9 ( 1 H, d, J = 8. 2 H z)
I R ( K Br): 3 3 1 2, 3 0 2 4, 2 9 3 6, 2 9 1 5,
1 6 5 3,  1 5 5 3 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 9 H 1 9 N 4 O ([ M + H] + ) 3 1 9. 1 5 5 9 ;
f ou n d 3 1 9. 1 5 8 8
1 1. 2 9 9. 4
3 6
N M R ( D M S O- d 6 , δ): 2. 1 7 ( 3 H, s), 3. 5 9 ( 2 H, s), 7. 1 3- 7. 2 1( 2 H, m), 7. 2 4- 7. 3 0 ( 4 H, m), 7. 5 2
( 1H, d, J  = 8. 7 H z), 7. 5 5 ( 1 H, d,J  = 2. 3 H z)
I R ( K Br): 3 2 6 3, 3 0 3 1, 2 9 1 4, 2 8 4 2,
1 6 5 4, 1 6 2 3, 1 5 5 6 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 8 H 1 6 Cl N 4 O ([ M + H] + ) 3 3 9. 1 0 0 7 ;
f ou n d 3 3 9. 0 9 7 8
1 3. 1 9 8. 9
3 7
N M R ( D M S O- d 6 , δ): 2. 1 7 ( 3 H, s), 3. 6 1 ( 2 H, s), 7. 1 3- 7. 2 2 ( 1 H, m), 7. 2 3- 7. 3 0 ( 4 H, m),
7 . 3 2 ( 1 H, d d, J  = 8. 2 a n d 1. 8 H z), 7. 4 9 ( 1 H, d, J  = 8. 2 H z), 7. 7 0 ( 1 H, d, J  = 1. 8 H z)
I R ( K Br): 3 0 3 0, 2 9 2 3, 2 8 5 0, 1 7 0 6,
1 6 3 7, 1 5 9 2, 1 5 7 6, 1 5 4 5, 1 5 0 9 c m -
1
E SI- H R M S ( n e g ati v e i o n, s o di u m f or m at e)
c a l c d f or C1 8 H 1 4 Br N 4 O ([ M- H] -) 3 8 1. 0 3 4 5;
f ou n d 3 8 1. 0 3 4 8
1 2. 6 9 7. 6
3 8
N M R ( D M S O- d 6 , δ): 2. 1 9 ( 3 H , s), 3. 6 0 ( 2 H, s), 7. 1 4- 7. 2 1 ( 1 H, m), 7. 2 4- 7. 3 1 ( 4 H, m),
7 . 4 6- 7. 5 2 ( 1 H, m), 7. 7 0 ( 1 H, d, J  = 8. 2 H z), 7. 8 4 ( 1 H, s)
I R ( K Br): 3 0 3 3, 2 9 3 5, 2 9 0 1, 1 6 3 7,
1 5 5 1 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 9 H 1 6 F 3 N 4 O ([ M + H] + ) 3 7 3. 1 2 7 1 ;
f ou n d 3 7 3. 1 2 5 9
1 3. 6 9 8. 8
3 9
N M R ( D M S O- d 6 , δ): 1. 3 3 ( 9 H, s), 2. 1 5 ( 3 H, s), 3. 5 9 ( 2 H, s), 7. 1 3- 7. 2 0 ( 1 H, m), 7. 2 2-
7 . 3 0 ( 5 H, m), 7. 4 3 ( 1 H, d, J = 8. 2 H z), 7. 5 1 ( 1 H, br s)
I R ( K Br): 3 0 2 6, 2 9 6 1, 2 9 0 3, 1 6 5 5,
1 5 5 8 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C2 2 H 2 5 N 4 O ([ M + H] + ) 3 6 1. 2 0 2 3 ;
f ou n d 3 6 1. 2 0 2 9
1 2. 5 9 7. 9
4 0
N M R ( D M S O- d 6 , δ): 2. 1 8 ( 3 H, s), 3. 6 1 ( 2 H, s), 7. 1 4- 7. 2 0 ( 1 H, m), 7. 2 4- 7. 3 6 ( 5 H, m),
7 . 4 3- 7. 5 0 ( 3 H, m), 7. 5 9 ( 1 H, d, J = 8. 2 H z), 7. 6 4- 7. 6 8 ( 2 H, m), 7. 7 6 ( 1 H, br s)
I R ( K Br): 3 3 3 8, 3 0 2 5, 2 8 9 7, 1 6 2 3,
1 5 7 7, 1 5 4 1 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C2 4 H 2 1 N 4 O ([ M + H] + ) 3 8 1. 1 7 1 0 ;
f ou n d 3 8 1. 1 7 1 6
1 3. 2 9 8. 4
4 1
N M R ( D M S O- d 6 , δ): 2. 1 8 ( 3 H, s), 3. 6 0 ( 2 H, s), 7. 1 4- 7. 2 0 ( 1 H, m), 7. 2 4- 7. 3 1 ( 4 H, m),
7 . 4 6 ( 1 H, d d, J = 1. 4 a n d 8. 2 H z), 7. 5 1 ( 2 H, d, J = 8. 4 H z, d), 7. 5 9 ( 1 H, d, J = 8. 2 H z),
7. 6 9 ( 2 H, d, J  = 8. 4 H z, d),  7. 7 6 ( 1 H, br s)
I R ( K Br): 3 3 0 8, 3 0 2 8, 2 9 1 5, 1 6 5 5,
1 5 5 5 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C2 4 H 2 0 Cl N 4 O ([ M + H] + ) 4 1 5. 1 3 0 2 ;
f ou n d 4 1 5. 1 3 2 7
1 4. 2 9 7. 1
4 2
N M R ( D M S O- d 6 , δ):  2. 1 7 ( 3 H, s), 2. 3 5 ( 3 H, s), 3. 6 0 ( 2 H, s), 7. 1 3- 7. 2 1 ( 1 H, m), 7. 2 3-
7 . 3 1 ( 6 H, m), 7. 4 3 ( 1 H, d d, J = 8. 2 a n d 1. 8 H z), 7. 5 1- 7. 5 9 ( 3 H, m), 7. 7 2 ( 1 H, br s)
I R ( K Br): 3 4 4 6, 3 0 2 7, 2 9 6 2, 2 8 7 3,
1 6 3 2, 1 5 5 6 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C2 5 H 2 3 N 4 O ([ M + H] + ) 3 9 5. 1 8 6 6 ;
f ou n d 3 9 5. 1 8 5 2
1 3. 6 9 8. 0
4 3
N M R ( D M S O- d 6 , δ): 2. 1 8 ( 3 H, s), 2. 5 2 ( 3 H, s), 3. 6 1 ( 2 H, s), 6. 9 5- 6. 9 9 ( 1 H, m), 7. 0 5
( 1H, t, J = 7. 8 H z), 7. 1 3- 7. 2 1 ( 1 H, m), 7. 2 2- 7. 3 0 ( 4 H, m), 7. 3 5 ( 1 H, d, J = 7. 8 H z)
I R ( K Br): 3 2 7 2, 3 0 2 7, 1 6 6 7, 1 6 2 8,
1 5 7 5  c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 9 H 1 9 N 4 O ([ M + H] + ) 3 1 9. 1 5 5 9 ;
f ou n d 3 1 9. 1 5 6 2
1 1. 9 9 8. 6
4 4
N M R ( D M S O- d 6 , δ): 2. 1 7 ( 3 H, s), 2. 3 1 ( 3 H, s), 2. 4 4 ( 3 H, s), 3. 6 1 ( 2 H, s), 6. 9 6 ( 1 H, d, J
=  7. 8 H z), 7. 1 2- 7. 3 0 ( 6 H, m)
I R ( K Br): 3 0 2 6, 2 9 2 0, 2 8 6 6, 1 6 7 7,
1 6 0 0 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C2 0 H 2 1 N 4 O ([ M + H] + ) 3 3 3. 1 7 1 0 ;
f ou n d 3 3 3. 1 7 2 6
1 2. 1 9 7. 4
4 5
N M R ( D M S O- d 6 , δ): 2. 1 7 ( 3 H, s), 2. 3 9 ( 3 H, s), 3. 6 9 ( 2 H, s), 6. 9 9 ( 1 H, d d, J = 0. 9 a n d
8. 2 H z), 7. 3 2 ( 1 H, br s), 7. 3 9 ( 1 H, d, J = 8. 2 H z), 7. 5 0 ( 2 H, d, J = 8. 2 H z), 7. 6 4 ( 2 H, d,
J = 8. 2 H z)
I R ( K Br): 3 2 6 8, 2 9 2 3, 2 8 6 5, 1 6 6 6,
1 5 5 2 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C2 0 H 1 8 F 3 N 4 O ([ M + H] + ) 3 8 7. 1 4 3 3 ;
f ou n d 3 8 7. 1 4 1 4
1 2. 4 9 9. 0
4 6
N M R ( D M S O- d 6 , δ): 2. 1 4 ( 3 H, s), 2. 3 9 ( 3 H, s), 3. 5 1 ( 2 H, s), 3. 7 0 ( 3 H, s), 6. 8 1- 6. 8 5
( 2H, m), 6. 9 6- 7. 0 0 ( 1 H, m), 7. 1 6- 7. 2 1 ( 2 H, m), 7. 3 1 ( 1 H, br s), 7. 3 9 ( 1 H, d, J = 8. 2 H z)
I R ( K Br): 2 9 2 1, 2 8 3 3, 1 6 7 3, 1 6 5 1,
1 5 8 3 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C2 0 H 2 1 N 4 O 2  ([ M + H]+ ) 3 4 9. 1 6 5 9 ;
f ou n d 3 4 9. 1 6 5 9
1 1. 0 9 8. 6
4 7
N M R ( D M S O- d 6 , δ): 2. 1 7 ( 3 H, s), 2. 3 9 ( 3 H, s), 3. 6 0 ( 2 H, s), 6. 9 8 ( 1 H, d d, J = 0. 9 a n d
8. 2 H z), 7. 2 7 ( 1 H, d d,  J = 1. 8 a n d 8. 2 H z), 7. 3 2 ( 1 H, br s), 7. 3 9 ( 1 H, d, J = 8. 2 H z), 7. 5 2
( 1 H, d, J  = 8. 2 H z), 7. 5 5 ( 1 H, d, J  = 1. 8 H z)
I R ( K Br): 3 0 5 0, 2 9 2 2, 2 8 6 5, 1 6 6 5,
1 5 6 1 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 9 H 1 7 Cl 2 N 4 O ([ M + H] + ) 3 8 7. 0 7 7 9 ;
f ou n d 3 8 7. 0 7 4 8
1 2. 7 9 7. 8
4 8
N M R ( D M S O- d 6 , δ): 2. 1 4 ( 3 H, s), 2. 4 0 ( 3 H, s), 3. 6 8 ( 2 H, s), 6. 9 9 ( 1 H, d, J  = 8. 2 H z),
7. 1 9- 7. 3 6 ( 4 H, m), 7. 3 6- 7. 4 5 ( 2 H, m)
I R ( K Br): 3 1 9 1, 2 9 2 4, 2 8 9 3, 1 6 7 4,
1 6 2 6, 1 6 0 4 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 9 H 1 8 Cl N 4 O ([ M + H] + ) 3 5 3. 1 1 6 3 ;
f ou n d 3 5 3. 1 1 7 5
1 2. 0 9 8. 8
4 9
N M R ( D M S O- d 6 , δ): 2. 1 5 ( 3 H, s), 2. 3 9 ( 3 H, s), 3. 5 8 ( 2 H, s), 6. 9 8 ( 1 H, d d, J  = 0. 9 a n d
8. 2 H z), 7. 2 7- 7. 3 5 ( 5 H, m), 7. 3 9 ( 1 H, d, J = 8. 2 H z)
I R ( K Br): 3 0 3 2, 2 9 2 1, 2 8 6 4, 1 6 6 5,
1 5 5 2 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 9 H 1 8 Cl N 4 O ([ M + H] + ) 3 5 3. 1 1 6 4 ;
f ou n d 3 5 3. 1 1 5 1
1 2. 0 9 8. 1
5 0
N M R ( D M S O- d 6 , δ): 2. 1 6 ( 3 H, s), 2. 3 9 ( 3 H, s), 3. 5 8 ( 2 H, s), 6. 9 8 ( 1 H, d d, J  = 0. 9 a n d
8. 2 H z), 7. 0 4- 7. 1 2 ( 2 H, m), 7. 2 6- 7. 3 4 ( 3 H, m), 7. 3 9 ( 1 H, d, J = 8. 2 H z)
I R ( K Br): 3 1 7 7, 3 0 4 0, 2 9 2 0, 1 6 6 7,
1 6 0 1 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C1 9 H 1 8 F N 4 O ([ M + H] + ) 3 3 7. 1 4 5 9 ;
f ou n d 3 3 7. 1 4 4 3
1 1. 4 9 8. 3
5 1
N M R ( D M S O- d 6 , δ): 1. 2 4 ( 9 H, s), 2. 1 6 ( 3 H, s), 2. 3 9 ( 3 H, s), 3. 5 4 ( 2 H, s), 6. 9 8 ( 1 H, d d,
J  = 0. 9 a n d 8. 2 H z), 7. 1 7- 7. 2 1 ( 2 H, m), 7. 2 5- 7. 2 9 ( 2 H, m), 7. 3 1 ( 1 H, br s), 7. 3 9 ( 1 H, d,
J = 8. 2 H z)
I R ( K Br): 3 2 3 3, 3 0 2 4, 2 9 6 1, 2 8 6 5,
1 6 5 8, 1 5 5 8 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C2 3 H 2 7 N 4 O ([ M + H] + ) 3 7 5. 2 1 7 9 ;
f ou n d 3 7 5. 2 1 8 4
1 3. 1 9 8. 4
5 2
N M R ( D M S O- d 6 , δ): 2. 1 9 ( 3 H, s), 2. 3 9 ( 3 H, s), 3. 6 3 ( 2 H, s), 6. 9 6- 7. 0 0 ( 1 H, m), 7. 3 0-
7 . 4 7 ( 7 H, m), 7. 5 4- 7. 6 4 ( 4 H, m)
I R ( K Br): 3 2 4 6, 3 0 3 1, 2 9 2 2, 2 8 6 4,
1 6 5 6, 1 5 5 7, 1 5 4 1 c m - 1
E SI- H R M S ( p o siti v e i o n, s o di u m f or m at e)
c a l c d f or C2 5 H 2 3 N 4 O ([ M + H] + ) 3 9 5. 1 8 6 6 ;
f ou n d 3 9 5. 1 8 3 4
1 2. 7 9 8. 3
*) H P L C c o n diti o n s
H P L C s y st e m ( T o s h o C o., Lt d,)
 A ut oi nj e ct or : A S - 8 0 2 0
 C o ul n o v e n  : C O - 8 0 2 0
 li q ui d mi x er   : C O - 8 0 2 0
 P u m p          : S D - 8 0 2 2 * 2
 U V d et e ct or : U V - 8 0 2 0
C ol u m n: Y M C - P a c k Pr o C 1 8 ( 1 5 0 x 4. 6 m m I D, S - 5 u m, 1 2 n m)
Gr a di e nt pr o gr a m
 0    3  1 3  1 5  1 5. 1  2 0  mi n
1 0  1 0  9 5  9 5  1 0    st o p  % a c et o nitril e i n 0. 1 % T F A a q.
fl o w: 1 ml/ mi n
d et e cti o n: 2 5 4 n m
